Guanfacine hydrochloride extended-release for attention deficit hyperactivity disorder a review of clinical effectiveness, cost-effectiveness, and guidelines
Since this time, Guanfacine hydrochloride extended-release's (GXR) role in attention-deficit/hyperactivity disorder (ADHD) therapy has continued to be studied. The aim of this review is to assist decision-makers and prescribers by evaluating the recently published evidence on the clinical effec...
| Main Authors: | , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, March 2018
|
| Edition: | Version 1.0 |
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Since this time, Guanfacine hydrochloride extended-release's (GXR) role in attention-deficit/hyperactivity disorder (ADHD) therapy has continued to be studied. The aim of this review is to assist decision-makers and prescribers by evaluating the recently published evidence on the clinical effectiveness and cost-effectiveness of GXR for the treatment children and adolescents with ADHD. Clinical guidelines will also be examined |
|---|---|
| Physical Description: | 1 PDF file (27 pages) |